Viela Bio spun out of AstraZeneca last year with six autoimmune and inflammation-aimed programs and $250 million. Now, the biotech is reporting positive pivotal data for its lead drug in a rare, autoimmune disease, teeing it up for an FDA filing later this year.
{iframe}https://www.fiercebiotech.com/biotech/promising-pivotal-data-viela-bio-s-lead-autoimmune-drug-heads-for-fda-filing{/iframe}